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The prevalence of negative symptoms (NS) at first 
episode of early-onset psychosis (EOP), and their effect 
on  psychosis prognosis is unclear. In a sample of 638 
children with EOP (aged 10–17 y, 51% male), we assessed 
(1) the prevalence of NS at first presentation to mental 
health services and (2) whether NS predicted eventual 
development of multiple treatment failure (MTF) prior 
to the age of 18 (defined by initiation of a third trial of 
novel antipsychotic due to prior insufficient response, 
intolerable adverse-effects or non-adherence). Data were 
extracted from the electronic health records held by child 
inpatient and community-based services in South London, 
United Kingdom. Natural Language Processing tools were 
used to measure the presence of Marder Factor NS and 
 antipsychotic use. The association between presenting 
with ≥2 NS and the development of MTF over a 5-year 
period was modeled using Cox regression. Out of the 638 
children, 37.5% showed ≥2 NS at first presentation, and 
124 (19.3%) developed MTF prior to the age of 18. The 
presence of NS at first episode was significantly associ-
ated with MTF (adjusted hazard ratio 1.62, 95% CI 1.07–
2.46; P = .02) after controlling for a number of potential 
 confounders including psychosis diagnostic classifica-
tion, positive symptoms, comorbid depression, and family 
 history of psychosis. Other factors associated with MTF 
included comorbid autism spectrum disorder, older age at 
first presentation, Black ethnicity, and family history of 
psychosis. In EOP, NS at first episode are prevalent and 
may help identify a subset of children at higher risk of 
responding poorly to antipsychotics.
Key words:  early-onset psychosis/first-episode 
psychosis/negative symptoms/antipsychotic 
agents/treatment resistance
Introduction
Early-onset psychosis (EOP), defined as onset before age 
18  years, is a severely debilitating condition associated 
with long-term psycho-social impairment.1 As a diagnos-
tic term, EOP covers a broad range of psychiatric illness 
including schizophrenia spectrum, affective and other 
non-affective psychotic disorders.2 Children with EOP 
often show significant levels of both positive and nega-
tive symptoms (NS) and disorganized behavior. Relative 
to adult-onset psychosis, children and adolescents are 
more likely to have a background of longer durations of 
untreated psychosis, poor pre-morbid adjustment, and 
greater number of co-existing conditions, such as neuro-
developmental and substance abuse disorders.3,4
Compared to work examining the pathogenesis of 
adult and EOP, studies which examine prognostic indi-
cators in the years following treatment initiation are 
relative scarce.1 From the research conducted, findings 
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suggest that both a longer duration of untreated psy-
chosis and poorer premorbid adjustment are associated 
with poorer recovery in EOP. Despite previous evidence 
from adult-onset samples supporting the influence of NS 
on functional outcomes and recovery, the effect of NS 
on the prognosis of EOP remains relatively unexplored. 
NS symptoms include lack of motivation, problems with 
social interaction or diminished emotional range, and 
involve a loss or deficit in normal functioning.5,6 They can 
be enduring and inherent to the core disease process (ie, 
primary NS), or caused by other factors such as medica-
tion side-effects, positive symptoms, concurrent depres-
sion, or limited social stimulation (ie, secondary NS).5,6
At present, it is difficult to assess the prognostic impli-
cations of NS at a young person’s first presentation 
with psychosis.1 In adult-onset cases, NS are reportedly 
present at first-episode psychosis in about 30%–50% of 
patients.7,8 They are difficult to treat and are one of the 
main contributors to the functional disability observed in 
psychotic illness.9–15 In EOP cases, NS are also reportedly 
stable over time, but little is known about the prevalence 
of these symptoms at first-episode.16 Most studies so far 
have focused on early-onset schizophrenia,17–19 which may 
not generalize to the heterogeneous population of young 
people that first present to child and adolescent early psy-
chosis intervention services. In addition, prior research 
findings have been limited by small sample sizes, conve-
nience recruitment of more severe cases, or inclusion of 
those more amenable to taking part in a research study.1,4
The digitization of mental health records across the 
world, presents an alternative resource for psychosis 
researchers who wish to study clinical issues “in vivo.”20 
A  major strength of these data is their comprehensive 
inclusion of the whole population of interest, and there-
fore providing highly generalizable results—addressing 
some of the limitations related to selection bias, sample 
size and attrition commonly found in the cohort studies 
described above. At present, NS research using electronic 
health records (EHR) has been limited. Despite a num-
ber of robust rating scales now available to assess NS in 
psychosis,21–23 they are inconsistently applied to clinical 
populations treated in routine practice.24,25
Computational linguistics or Natural Language 
Processing (NLP) explores how to make computer sys-
tems understand and manipulate natural language 
expressed in text to perform desired tasks.26 Phenotype 
algorithms using NLP within clinical text, are an emerg-
ing method of automatically classifying patients with 
specific diseases, symptoms and outcomes.27 NLP 
approaches can discern the meaning or semantic content 
of text, and using pre-specified algorithms, encode text 
to provide structured output for analysis. This provides 
considerable advantages compared to performing key 
word searches in EHR, especially when accurately target-
ing certain clinical phenotypes.27 For example, NLP can 
discern whether a key word emotional withdrawal in the 
health record refers to a patient or family member, their 
current or past mental state, or is simply a negated item 
within clinical screening. NLP approaches can use pat-
tern recognition via statistical or machine learning meth-
ods to identify a phenotype or exposure of interest within 
the EHR. Parameters around accuracy can be stipulated, 
allowing uncertainty on whether an event or phenotype is 
a true positive, which can be accounted in later analysis. 
Investigators have largely adopted this approach in i2b2 
(Informatics for Integrating Biology and the Bedside), a 
US consortium, based at Harvard/MIT Health Science 
division and Partners HealthCare System in Boston, 
MA.28
In a large naturalistic sample of children and adoles-
cents first presenting to services with EOP, we examined 
the prevalence of NS recorded in the mental health record 
at initial contact with psychiatric services. To address the 
limited structured information available on NS, we used a 
machine-learning NLP approach, validated in adult sam-
ples, to extract NS data within the EHR. To explore NS as 
potential prognostic indicator, we examined whether NS 
at first episode predicted antipsychotic treatment failure, 
using a pragmatic measure of treatment failure, as defined 
by initiation of a third trial of novel antipsychotic (due 
to prior insufficient response, intolerable adverse-effects 
or non-adherence), which we termed multiple treatment 
failure (MTF).29 Previous work in adult-onset samples, 
suggests that NS characterize psychotic disorders with 
non-hyperdopaminergic pathophysiology,30,31 which is 
supported by clinical evidence that NS in the first-episode 
are associated with poorer response to antidopaminergic 
effects of current antipsychotic treatment.30,32 Therefore, 
we predicted that EOP patients with NS at presenta-
tion would be more likely to experience MTF. We also 
expected that this association would remain after tak-
ing account of potential confounders, including type of 
psychotic disorder, positive symptoms, family history of 
psychosis, comorbid depression, and additional markers 
of premorbid neurodevelopmental difficulties such as 
co-occurring autism spectrum disorders (ASD), hyperki-
netic disorder and intellectual disability.
Methods
Study Design and Study Sample
A complete description of the study design and sample 
selection is provided elsewhere.29 In brief, the sample con-
sisted of a clinical cohort of all those individuals with a 
first episode of any psychotic disorder who were referred to 
child and adolescent mental health services (CAMHS)—
including inpatient, outpatient, and early intervention 
for psychosis services—in South London and Maudsley 
NHS Foundation Trust (SLaM), United Kingdom, from 
January 1, 2008 to December 31, 2014. Over this time, 
SLaM delivered all aspects of inpatient and community-
based child mental healthcare to approximately 250 000 
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children residing in 4 London boroughs, and special-
ist provision to children resident outside the boroughs 
where local area services (such as inpatient facilities) were 
unavailable. Most children experiencing a psychotic dis-
order within the SLaM catchment area of South London 
were likely to present to SLaM services and included in 
this study: the private sector has very limited involvement 
in child mental health within the area, and children with 
psychosis, relative to adults, usually come to the attention 
of services relatively early.33
The data were extracted using the Clinical Record 
Interactive Search (CRIS) application: a de-identified 
record database containing the EHR of over 34 400 child 
and adolescent cases held at the UK National Institute 
for Health Research (NIHR) Biomedical Research Centre 
(BRC) for Mental Health.34,35 Data from structured text 
fields was extracted and missing structured data was 
supplemented by NLP tools (Generalised Architecture 
for Text Engineering [GATE]36 and TextHunter37) which 
code “free text” from the EHR (ie, progress notes, men-
tal state assessments, discharge summaries, outpatient 
correspondence). The CRIS resource was an approved 
as anonymized data resource for secondary analy-
sis by Oxfordshire Research Ethics Committee C (08/
H0606/71+5). This study was approved under NIHR 
BRC CRIS oversight committee (ref: CRIS 14–095).
Inclusion Criteria
Inclusion criteria for participants were: (1) age 
10–17 years at the time of  first presentation to CAMHS 
(owing to ethical considerations and risk of  statistical 
disclosure, we did not include children who were under 
the age of  10 y); (2) at least one “clinically relevant” psy-
chotic disorder diagnosis, based on clinician judgment 
after comprehensive diagnostic interviews and identified 
from either clinician-recorded structured fields (ICD-10 
codes F20-F29, F30-31, F32.3, F33.3, F1x.5); or any 
free text clinician-recorded ICD-10 diagnosis of  “schizo-
phrenia,” “schizoaffective disorder,” “bipolar disorder,” 
“depression with psychotic symptoms,” “brief  psychotic 
disorder,” “delusional disorder,” “shared psychotic dis-
order,” “drug-induced psychosis,” and “psychosis not 
otherwise specified (NOS),” filtered for any clinician-
recorded mention of  antipsychotic treatment after the 
psychosis diagnosis. The earliest recorded psychosis 
diagnosis was coded as the first-episode diagnosis. For 
reporting purposes, diagnoses were grouped into schizo-
phrenia, schizoaffective disorder, bipolar disorder, psy-
chotic depression, drug-induced psychosis, and other 
psychoses (including brief  psychotic disorder, delusional 
disorder, shared psychotic disorder, and psychoses-
NOS). A hand-searched review of a random sample of 
100 records revealed that this identification process had a 
0.98 positive predictive value (PPV) for psychosis.
Figure 1 shows the flowchart for inclusion in the study. 
Out of the 1033 cases initially identified with the GATE 
tool or through structured diagnoses, only 638 individu-
als met the inclusion criteria for a “clinically relevant psy-
chotic disorder” and age 10–17 years and were therefore 
included, whilst 395 were excluded due to psychosis refer-
ring to non-primary/differential diagnosis or subthresh-
old symptoms.
Extraction of Antipsychotic Use Data and Definition 
of MTF
As described elsewhere,29 we used a previously validated 
GATE application to identify regular antipsychotic pre-
scription trials from the structured medication fields 
and unstructured fields in the EHR.38,39 Since no stan-
dard criteria for poor antipsychotic response or refrac-
tory disorder appeared suitable for EOP samples,40,41 a 
proxy was created, based on the antipsychotic effective-
ness literature,42–44 which we termed MTF; defined as the 
initiation of a third trial of a novel antipsychotic due 
to insufficient response, intolerable adverse effects, non-
adherence, or other miscellaneous reasons over a 5-year 
follow-up period from first presentation, or before the age 
of 18 years, whichever came first. Please see Downs et al29 
for further details around the validation of the MTF out-
come and reasons for discontinuation.
Extraction of NS Data
A previously validated NLP method8 was used to find 
statements in the unstructured free-text fields of patients’ 
EHR which related to the presence of NS at baseline (ie, 
within 60 d of accepted referral). The method was based 
on a NLP tool called TextHunter (see Jackson et al37 for 
further details) which is a custom-built NLP software 
tool which interfaces with CRIS. It facilitates each of 
the steps involved in developing a NLP application,27 
from identifying appropriate ontologies and supporting 
manual annotation, to applying and testing sophisticated 
text-based pattern recognition (including support vector 
machine learning approaches) derived from annotated 
training datasets.
To validate the NLP data extraction, the random-
ized sample of 100 cases used previously was also 
hand-searched for NS by a master’s level graduate in 
Early Intervention Psychosis studies (H.D.), blinded 
to MTF status. The PPV for NS subtypes ranged from 
0.80 (poverty of speech) to 0.99 (mutism) and sensitiv-
ity ranged from 0.62 (poor motivation) to 0.97 (apathy). 
For the purposes of this study, Marder negative factor 
items21,45 from the Positive and Negative Syndrome Scale 
(PANSS)23 were used as a framework for characterizing 
NS (see table  1 for details). The extracted item “social 
isolation” was considered descriptive of both passive apa-
thetic social withdrawal (Marder N4) and active social 
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avoidance (Marder G16). Having mutism, poverty of 
speech or both items recorded on the EHR was counted 
as a single NS, equivalent to lack of spontaneity / flow 
of conversation (Marder N6). The item psychomotor 
retardation (equivalent to Marder G7) was dropped as 
an NS due to its low PPV (0.55) and sensitivity (0.65). 
Furthermore, the hand search of the selected 100 cases 
revealed that this item had a low prevalence (~5% of the 
sample) and always appeared acknowledged as an anti-
psychotic-related adverse effect (hence a secondary NS).
A composite ordinal variable, “number of NS” (range 
0–5) was created by summing the total count of the 
extracted NS. A score of at least 2 NS was applied a priori 
to determine the presence or absence of NS for analysis. 
Sensitivity analyses restricted to samples:
1) Adjusting for fully complete adaptive 
function measures and residence within the 
local catchment.
2) Admitted patients at baseline assessment
Cases reaching MTF threshold within 60 
days of entering the study (n=20)
All MTF case notes hand 
searched and reasons coded.
0.99 sensitivity, 0.74 positive 
predictive value for MTF
638 cases
19.7% (n=124) with 
MTF within 5 years
Survival 
Analysis 
(n=618)
MTF
validation
43 cases re-recoded as non 
MTF within 5 years or before 
18 years old, whichever came 
first
1033 cases < 18 years old identified 
with at least one psychotic disorder 
reference in the electronic health 
record
Filter applied for ‘clinically relevant’ 
psychotic disorder between 10-17 years
Included cases
N= 638
(61% from structured 
diagnostic fields)
Natural language extraction of ‘possible’ 
MTF outcome
395 children and adolescents 
excluded as psychoses described as 
non-primary differential diagnosis, 
or with sub-threshold / incidental 
symptoms
638 cases, 26.2% (n=167) initially 
identified with MTF
Fig. 1. Flowchart of study selection and analysis.
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Individuals were categorized as having an NS or non-NS 
profile using the ≥2 Marder Factor NS cut-off. This was 
consistent with previous work that used the 2-symptom 
cut-off  to describe deficit syndromes in schizophrenia (ie, 
primary, enduring NS).8,13
Extraction of Other Clinical and Demographic Data
A number of demographic variables and clinical data 
within 60 days of study entry (ie, after accepted referral) 
were also extracted from the health record. Age at referral 
for first-episode psychosis, gender, ethnicity (according to 
categories defined by the UK Office for National Statistics), 
and index of neighborhood deprivation for the main care-
giver residence were extracted.46 Data on positive symp-
tom severity around first presentation were extracted using 
TextHunter (see Jackson et al. 201747 for validation metrics) 
which provided the total number of items in the EHR refer-
encing positive symptoms of psychosis including delusions, 
persecutory and paranoid ideation, and hallucinations. 
Based on the total number of items referenced, individuals 
were then categorized into quartiles. As an additional index 
of severity we coded inpatient status and the Children’s 
Global Assessment Scores (CGAS),48 respectively at study 
entry.29 Data on ICD-10 comorbid neuropsychiatric disor-
ders which can be subsumed under the DSM-5 category 
of ASD (F84.0, F84.1, F84.5, F84.9), hyperkinetic dis-
order (F90.0, F90.1, F90.2, F90.8, F90.9), major depres-
sive disorder (F32-33), and intellectual disability (F70-79), 
were also extracted from free text and structured fields as 
previously described.29 TextHunter also retrieved positive 
mentions of substance misuse around first presentation, 
with validation metrics (PPV) for the following Cannabis 
(0.70), Cocaine or crack (0.78), Amphetamine (0.76), and 
3,4- Methylenedioxymethamphetamine (MDMA, 0.88); a 
binary “any use” variable was created for each substance 
type. Using the GATE tool, we also built a rules-based 
NLP application which coded absence/presence of a 1st 
degree relative with psychosis (defined as any of the study 
inclusion terms for psychosis but affecting parents or full 
siblings). Validation of this NLP approach was conducted 
against clinician review (JD & LP) of all patient notes from 
96 randomly selected EOP cases (PPV 0.91, recall 0.73).
Statistical Analyses
All analyses were conducted using STATA (Version 13). 
The prevalence of individuals meeting ≥2 threshold 
NS, and the total number of NS items was calculated. 
Logistic regression was used to examine the demographic 
and baseline clinical association with ≥2 NS profiles.
To examine the prospective association between baseline 
demographic, clinical exposures and MTF outcome, we 
excluded children who had MTF within the 60-day baseline 
period (n = 20). Kaplan–Meier curves were used to illus-
trate survival over time (probability of non-development of 
MTF), comparing those who were and were not present-
ing with ≥2 NS at baseline. After checking proportional 
hazards assumptions, we used a Cox regression to model 
the association between this baseline NS profile and MTF 
over a 5-year follow-up period from first presentation, or 
before the age of 18 years, whichever came first. The first 
model examined the crude effect of NS alone on MTF. 
Subsequent models were constructed adding potential 
socio-demographic, and clinical confounders. As sampling 
bias towards more severe cases could affect the external 
validity of the findings, sensitivity analyses were conducted 
to (1) adjust the aforementioned models by adaptive func-
tion (CGAS) measures at first presentation and local catch-
ment area residence status; (2) restrict to patients who were 
inpatients at baseline assessment.
Results
Demographic and Clinical Characteristics of 
the Sample
Demographic and clinical characteristics of  the 638 
patients included (124 [19.3%] of  whom developed 
MTF over time) and of  the NS subgroup are presented 
in table 2.
Table 1. Selection of Negative Symptoms From Electronic Health Records and Their Equivalence to the Marder Negative Factor Items 
Within the PANSS
Items Extracted From Electronic Health Record PPV/Sensitivity Marder Negative Factor Items Within the PANSS
Blunted affect 0.93/0.83 N1. Blunted affect
Emotional withdrawal 0.85/0.74 N2. Emotional withdrawal
Poor rapport 0.91/0.77 N3. Poor rapport
Social isolation 0.94/0.96 N4. Passive apathetic social withdrawal
G16. Active social avoidance
Poverty of speech 0.80/0.73 N6. Lack of spontaneity and conversation flow
Mutism 0.99/0.94
Psychomotor retardation (droppeda) 0.55/0.65 G7. Motor retardation
Note: PANSS, Positive and Negative Syndrome Scale; PPV, positive predictive value.
aDropped from the study due to low PPV (0.55) and sensitivity (0.65) of the “free text” extraction tool, and due to its being recorded 
mainly as secondary negative symptom.
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NS Prevalence
Supplementary material 1 shows the prevalence of each 
NS and positive symptom, and summary statistics for each 
item using the manually-validated NLP extraction tool, in 
the total sample and the MTF subgroup. Of note, 52.4% of 
the MTF subgroup presented with ≥2 Marder Factor NS. 
The most prevalent NS in the MTF subgroup was emo-
tional withdrawal (43.6%). The prevalence of ≥2 Marder 
Factor NS across diagnostic categories were as follows: 
schizophrenia- 39.2%, schizoaffective disorder- 35.3%, 
bipolar disorder- 26.1%, psychotic depression- 37.7%, drug-
induced psychosis- 25.6%, and other psychoses- 40.6%.
Reasons for Antipsychotic Discontinuation
Details on the antipsychotic treatment pathways for the 
124 children who developed MTF are shown as supple-
mentary material 2. Cases identified as having the same 
Table 2. Comparison Between Young People With Early-Onset Psychosis at First Presentation With and Without ≥ 2 NS Documented
Sample Characteristics Non-NS Group (n = 399) NS Group (n = 239) OR; P-value
MTF status, N (%) 59 (14.8) 65 (27.2) 2.15 (1.45–3.20)***
Gender, female, N (%) 192 (48.1) 117 (48.9) 1.03 (0.75–1.42)
Age at referral (mean, SD) 15.4 (1.9) 15.9 (1.9) 1.17 (1.06–1.28)***
Age of reaching MTF (mean, SD) 16.5 (1.3) 16.0 (0.19) 0.79 (0.61–1.04)
Duration of follow-up (d), mean (SD) 721.4 (529.9) 590.5 (458.0) 0.995 (0.991–0.998)**
Ethnicity, N (%)
 White 204 (51.1) 93 (38.9) Reference
 Black 113 (28.3) 96 (40.2) 1.86 (1.29–2.67)
 Asian 18 (4.5) 21 (8.8) 2.56 (1.30–5.03)
 Mixed 47(11.8) 27(11.3) 1.26 (0.74–2.15)
 Not Stated 17 (4.3) 2 (0.8) 0.25 (0.06–1.14)
Neighborhood characteristics, N (%)a
 1st (least deprived) 104 (27.1) 61 (25.9) Reference
 2nd 90 (23.4) 62 (26.4) 1.17 (0.75–1.42)
 3rd 94 (24.5) 57 (24.3) 1.03 (0.66–1.63)
 4th (most deprived) 96 (25.0) 55 (23.4) 0.98 (0.62–1.54)
First ICD-10 psychosis diagnosis, N (%)
 Other psychosesb 63 (15.8) 43 (17.9) Reference
 Bipolar disorder / F30, F31 31 (7.8) 11 (4.7) 0.57 (0.24–1.15)
 Drug-induced psychosis / F1x.x5 29 (7.3) 10 (4.2) 0.51 (0.22–1.14)
 Schizophrenia / F20 222 (55.6) 143 (59.8) 0.94 (0.61–1.46)
 Schizoaffective / F25 11 (2.8) 6 (2.5) 0.80 (0.27–2.32)
 Psychotic depression / F32.3, F33.3 43 (10.8) 26 (10.9) 0.89 (0.47–1.65)
Comorbid neuropsychiatric disorders, N (%)
 Autism spectrum disorder 75 (18.8) 39 (16.3) 0.84 (0.55–1.29)
 Hyperkinetic disorder 33 (8.3) 7 (2.9) 0.33 (0.15–0.77)**
 Intellectual disability 43 (10.8) 22 (9.2) 0.84 (0.49–1.44)
 Major depressive disorder 108 (27.1) 66 (27.6) 1.03 (0.72–1.48)
First degree relative with psychotic disorder 86 (21.6) 51 (21.3) 0.99 (0.67–1.46)
Illness severity/ functioning
 Admission at presentation, N (%) 90 (22.6) 170 (71.1) 8.5 (5.9–12.2)***
 CGAS score (mean, SD)c 42.1 (15.3) 33.7 (15.4) 0.97 (0.95–0.98)***
Positive symptoms
 1st (lowest quartile of symptom items recorded) 61 (15.3) 11 (4.6) Reference
 2nd 79 (19.8) 27 (11.3) 1.90 (0.87–4.21)
 3rd 137 (34.3) 84 (35.2) 3.40 (1.69–6.83)***
 4th (highest quartile of symptoms items recorded) 122 (30.6) 117 (49.0) 5.31 (2.67–10.6)***
Substance misuse
 Cannabis 171 (42.9) 113 (39.5) 1.20 (0.87–1.65)
 Cocaine or crack 65 (16.3) 39 (16.3) 1.02 (0.65–1.54)
 Amphetamines 14 (3.5) 5 (2.1) 0.59 (0.21–1.65)
 MDMA 12 (3.0) 4 (1.7) 0.55 (0.18–1.72)
Note: CGAS, Children’s Global Assessment Scale; MTF, multiple treatment failure; MDMA, 3,4- Methylenedioxymethamphetamine; 
NS, negative symptoms.
aMissing cases =19.
bData available in a subsample of 384.
cOther Psychoses: an ICD-10 diagnosis of “brief  psychotic disorder,” “delusional disorder,” “shared psychotic disorder,” or “psychosis 
not otherwise specified (NOS).”
**P < .01; ***P < .001; % Refers to percentages within columns, for whom information was available.
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reason for antipsychotic discontinuation at first and sec-
ond antipsychotic trials were grouped into 3 MTF “per-
sistent reason” groups (persistent insufficient response, 
adverse events or non-adherence). A “variability in rea-
sons” subgroup (ie, when reasons were different at each 
antipsychotic trial) was also created. The main patterns 
of  discontinuation in the MTF group were the combina-
tion of  insufficient response and adverse events (n = 32, 
35.2%), and persistent adverse events (n = 19, 20.9%) 
over time. Children with NS profile showed higher rates 
of  the “insufficient response-and-adverse effect” trajec-
tory and lower rates of  adherence-related trajectories 
relative to those with non-NS profile (supplementary 
material 2).
Cox Regression Models
Kaplan-Meier curves displaying the survival status (prob-
ability of treatment effectiveness or non-MTF) over time 
of children with or without baseline NS profiles are pre-
sented as figure 2. A log-rank test showed non-NS pro-
file at first presentation to services displayed significantly 
higher survival rate (P < .001). Unadjusted associations 
using a Cox regression model between MTF outcomes 
and predictor variables, including NS and other co-
variates, are displayed in supplementary material 3. An 
adjusted Cox regression model (table 3) showed that NS 
profile was associated with increased risk of MTF over 
the follow-up period (adjusted hazard ratio [aHR] 1.62, 
95% CI 1.07–2.46; P = .02). Black ethnicity (aHR 1.78, 
95% CI: 1.11–2.87; P = .02), older age at first presenta-
tion (aHR 1.27, 95% CI: 1.109–1.49; P =  .002), comor-
bid diagnosis of ASD (aHR 1.70, 95% CI: 1.03–2.79; 
P = .04), and first degree relative with psychotic disorder 
(aHR 2.11, 95% CI: 1.35–3.30; P = .001) were also signifi-
cantly associated with MTF.
Sensitivity Analyses
A sensitivity analysis with adjustment for all those with 
complete CGAS information and residence within the 
local catchment area (n  =  394), found NS profile was 
associated with increased risk of MTF (aHR = 1.85; 95% 
CI = 1.02–3.48; P = 03). The analyses including only those 
individuals who were inpatients (n = 260, 40.8%) at first 
presentation (within 60 d of accepted referral) found little 
change in the direction and magnitude of the association 
between NS and MTF (aHR = 1.63; 95% CI = 0.82–3.22; 
P = .16), although the reduced sample affected the power 
of the study to detect a significant association.
Discussion
This study shows that children and adolescents with psy-
chosis commonly present with NS, with more than one-
third of the sample displaying NS at first presentation to 
services. Our results also show that an NS profile at first 
stages is a prognostic marker for antipsychotic treatment 
failure in children with EOP: approximately 30% of the 
sample with NS at baseline went on to develop MTF, rep-
resenting a 2-fold increased risk from those without NS. 
The treatment pathway to MTF for young people with 
NS profiles appears to be driven by a combination of 
limited treatment response and emergence of intolerable 
adverse effects. Older age at first episode, Black ethnic-
ity and a comorbid diagnosis of ASD are also significant 
predictors of MTF in our sample.
This is, to our knowledge, the largest naturalistic study 
of its kind to examine the prevalence of NS in EOP at 
first presentation to child mental health services. The 
study used an innovative text mining technique, adapted 
from an application in adult mental health records,8 to 
extract NS profiles. In our study, more than one-third of 
the EOP population had 2 or more NS at baseline, rates 
that are consistent with those reported in both child and 
adult-onset psychosis literature (around 30%–50%).8,49
This is also the first study to assess the association of NS 
and antipsychotic treatment failure in first-episode EOP 
patients. Our results, combined with findings that NS can 
manifest in the psychosis prodrome,50 suggests that NS 
profiles could represent a distinct phenotypic trajectory 
in young people with psychotic disorders. NS are possibly 
a marker for a distinct deviant neurodevelopmental tra-
jectory which may be harder to treat with conventional 
antipsychotics and therefore result in a more impaired ill-
ness course. Although no other cohorts have been used 
to examine MTF as an outcome in EOP, our findings are 
consistent with evidence that NS are associated with poor 
clinical outcomes in adult and child samples, many of 
those using validated gold-standard instruments to mea-
sure NS (eg, the PANSS).1,51 Our work using text mining 
approaches for NS identification in large scale naturalis-
tic samples of EOP using EHRs serves to complement 
Fig. 2. Kaplan-Meier curves displaying the survival status 
(probability of treatment effectiveness or non-MTF) over time 
of children with or without negative symptom profiles at first 
presentation to services.
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the more traditional approaches using selective cohorts 
and intensive structured assessments, to inform prognos-
tic indicators in clinical practice.
Several alternative psychopathological processes may 
be driving our findings. Higher levels of primary NS may 
represent a clinical phenotype for greater levels of “non-
hyperdopaminergic” processes behind psychosis develop-
ment and/or remission.30,31,52 Hence, NS may help identify 
a subgroup of patients with positive symptoms who do not 
respond well to antipsychotics, and are at higher risk of 
developing MTF. Our findings suggest NS in adolescents, 
alongside other factors including ethnicity, family history 
and neurodevelopmental comorbidity may delineate “hard 
to treat” subgroups. These groups may benefit from more 
careful monitoring and quicker access to additional inter-
ventions beyond antipsychotic medication.53 Follow-up 
was conducted for the sample for up to 5  years, so it is 
important to understand that antipsychotic medication 
may still successfully reduce positive psychotic symp-
toms in these groups, but NS and other MTF risk factors 
may moderate the association between positive symptom 
reduction and the protective factors required for a sus-
tained remission. Our findings also highlight the need for 
research involving agents that work on alternative patho-
physiological pathways (eg, the glutamate system) which 
may be of greater relevance to these subgroups, given their 
potential effectiveness at treating both the NS and the pos-
itive symptoms of those with psychosis.
Table 3. Cox Regression Models for the Association Between Negative Symptom Profile at First Presentation and Multiple Treatment 
Failure Over Time in Early-Onset Psychosis (n = 618)
Multiple Treatment Failure
Socio-demographic adjustment 
aHR (95% CI)
+ Diagnosis and Severity 
aHR (95% CI)
+ Substance Misuse and Family 
History aHR (95% CI)
≥2 baseline Marder NS 1.66 (1.12–2.42)* 1.59 (1.06–2.40)* 1.62 (1.07–2.46)*
Female gender 1.08 (0.73–1.62) 1.15 (0.76–1.74) 1.07 (0.71–1.64)
Mean age at referral (SD) 1.25 (1.09–1.45)** 1.29 (1.10–1.49)** 1.27 (1.09–1.49)**
Ethnicity, N (%)
 White Reference Reference Reference
 Black 1.95 (1.23–3.09)** 1.72 (1.08–2.76)* 1.78 (1.11–2.87)*
 Asian 1.16 (0.48–2.77) 1.10 (0.46–2.67) 1.33 (0.58–3.26)
 Mixed 1.51 (0.80–2.86) 1.43 (0.75–2.73) 1.63 (0.84–3.17)
 Not stated —a — —
Neighborhood characteristics, N (%)a
 1st (least deprived) Reference Reference Reference
 2nd 0.60 (0.35–1.04) 0.69 (0.39–1.19) 0.66 (0.37–1.17)
 3rd 0.55 (0.31–0.96)* 0.61 (0.35–1.08) 0.56 (0.31–0.98)
 4th (most deprived) 0.55 (0.31–0.97)* 0.61 (0.34–1.08) 0.62 (0.34–1.11)
First ICD-10 psychosis diagnosis, N (%)
 Other psychosesb Reference Reference
 Bipolar disorder / F30, F31 1.57 (0.69–3.56) 1.54 (0.67–3.56)
 Drug-induced psychosis / F1x.x5 0.82 (0.27–2.51) 0.92 (0.29–2.96)
 Schizophrenia / F20 0.85 (0.50–1.45) 0.78 (0.45–1.32)
 Schizoaffective / F25 2.42 (0.87–6.85) 2.22 (0.78–6.34)
 Psychotic depression / F32.3, F33.3 1.39 (0.62–3.08) 1.15 (0.50–2.60)
Comorbid neuropsychiatric disorders, N (%)
 Autism spectrum disorder 1.73 (1.06–2.82)* 1.70 (1.03–2.79)*
 Other neurodevelopmental disorder 0.74 (0.41–1.33) 0.68 (0.38–1.24)
 Major depressive disorder 0.68 (0.39–1.15) 0.69 (0.41–1.20)
Positive symptoms
 1st (lowest quartile) Reference Reference
 2nd 0.89 (0.36–2.15) 0.83 (0.32–2.13)
 3rd 1.18 (0.53–2.65) 1.09 (0.48–2.46)
 4th (highest quartile) 1.97 (0.92–4.21) 1.83 (0.84–3.98)
First degree relative with psychotic 
disorder
2.11 (1.35–3.30)**
Substance misuse
 Cannabis 1.07 (0.67–1.70)
 Cocaine or crack 0.68 (0.36–1.31)
 Amphetamines 1.20 (0.27–5.43)
 MDMA 0.55 (0.07–4.34)
Note: HR, hazard ratio; MTF, multiple treatment failure; MDMA, 3,4- Methylenedioxymethamphetamine; NS, negative symptoms.
aVariable dropped due to 0 values in cell.
bSee corresponding footnote table 2.
*P < .05; **P < .01.
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Our findings support the notion that NS are intrinsic 
to EOP (across different psychosis diagnostic categories) 
and are already present during the first psychotic break. 
In regard to the prevalence across the different psychosis 
disorder classifications, in our sample NS were present in 
about one-third of all EOP diagnostic subgroups, with 
slightly higher rates in those with non-affective psychosis. 
This suggests that in EOP, differences between psycho-
sis diagnostic categories (especially between schizophre-
nia and affective psychoses) are quantitative rather than 
qualitative in nature, and all diagnoses are associated 
with presence of impairing symptoms (as reflected by 
similar rates of NS). Further research using transdiag-
nostic approaches, as illustrated in this study, are needed 
to advance in the understanding of the physiopathology 
and predictive value of NS across disorders.
The main strengths of this study include the use of a 
large historical cohort of first-episode EOP, which pro-
vides a “real world” sample of young people accessing 
inpatient and outpatient first episode psychosis CAMH 
services. Selecting an early-onset sample at first episode, 
reduces the potential bias incurred through unknown 
treatment exposures. The large sample size, and relative 
long duration of assessment provides sufficient power to 
estimate the association between NS and MTF even after 
adjustment for a number of potential clinical confound-
ers, including psychotic disorder classification, family 
history, positive symptoms, substance misuse, neurode-
velopmental and depressive disorder comorbidity. Using 
a clinical rater review of the whole EHR for sub-sets of 
patients allowed us to compute performance estimates of 
the different text extraction tools used in the study and 
select the most accurate ones, and mitigation of misclas-
sification errors. This work using text mining approaches 
for NS identification in large scale naturalistic samples 
of EOP using EHRs serves to complement the more tra-
ditional approaches using selective cohorts and intensive 
structured assessments, to inform prognostic indicators 
in clinical practice. It is important to recognize that even 
the most accurate NLP applications will be limited by the 
text held within clinical records, and unlikely to identify 
NS as accurately as specialized rating scales. However, as 
with most structured psychiatric assessments, clinicians 
tend to shun structured templates or drop-down options 
when keeping a record of their daily practice,54,55 so the 
free-text note persists as the predominant method of 
recording clinical information.56 This was certainly re-
flected in our EOP samples, as we were unable to detect 
any young people who had undergone a comprehensive 
assessment for NS using a standardized instrument at 
first presentation.
Results derived from the EOP sample should be inter-
preted in the context of  several limitations, some of  which 
have been covered in previous work.29 In relation to the 
findings specific to this study, it was difficult to ascer-
tain whether extracted NS were primary or secondary in 
nature, we assume that as NS were rated early (ie, within 
60 d of  presentation to services and potentially prior or 
at the point of  starting initial antipsychotic treatment), 
and excluding the presence of  psychomotor retardation 
from the total NS counting, the NS we detect are mainly 
(but not only) primary in character. In regard to the MTF 
definition, we were unable to obtain relevant antipsy-
chotic data such as maximum daily antipsychotic dose, 
antipsychotic serum levels, or structured assessments 
of  tolerability, which may have provided more objective 
assessments of  treatment failure. Besides, by rating treat-
ment failure to 1 of  4 potential categories at each point of 
discontinuation/treatment failure, we may have underes-
timated the contribution of  other underlying reasons to 
treatment failure. As with all observational studies, our 
findings may be limited by residual confounding, eg, we 
were unable to adjust for the duration of  untreated psy-
chosis—which could be explanatory factors for older age 
being associated with MTF. Another related limitation 
includes the restriction of  age to the clinical samples, so 
that all clinical outcomes occurred prior to age 18. One 
of  the reasons we imposed this was to reduce the impact 
of  clinician heterogeneity as a residual confounder. 
Children with long-term conditions, such as psychosis, 
experience very different treatment environments when 
they move from CAMHS to adult psychiatric services,57 
and this heterogeneity may have considerable influence 
on the way clinical data is recorded, as well as the men-
tal health treatments offered and outcomes obtained.58 
Finally, there is a chance that not all children and ado-
lescents experiencing a first-episode psychosis within 
the catchment area (who access clinical services) would 
have presented to SLaM CAMHs, nor given potential 
changes in residence away from SLaM services, were all 
young peoples’ psychiatric care captured by the health 
record system over the course of  follow-up. Given the 
mean duration of  follow-up was lower in the NS group, 
we suspect that this may have led to an underestima-
tion of  the NS-MTF effect we report. Furthermore, the 
impact of  potential loss to follow-up or of  non-actual 
first presentation to services is likely to be limited, as we 
conducted a sensitivity analyses which took account of 
residence within the local catchment which showed little 
difference from whole sample findings.
In summary, our study demonstrated that there is a high 
prevalence of NS in EOP around patients’ first presenta-
tion to services and across psychosis diagnosis classifica-
tions. The finding supports the hypothesis that presence 
of these symptoms around the first stages of the illness 
identify a subset of children and adolescents who may 
be at higher risk of responding poorly to antipsychotics, 
both through refractory symptoms and high sensitivity 
to side-effects. Optimization of current pharmacological 
and non-pharmacological strategies for these patients, 
and further research involving agents that better target 
NS are warranted.
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Supplementary data are available at Schizophrenia 
Bulletin online.
Funding
J.D.  received supported by a Medical Research Council 
(MRC) Clinical Research Training Fellowship (MR/
L017105/1) and Psychiatry Research Trust Peggy Pollak 
Research Fellowship in Developmental Psychiatry. H.D. and 
S.L.  have received salary support from the Foundation of 
Professional Services to Adolescents, UK. R.D.H.  was 
funded by an MRC Fellowship (MR/J01219X/1). R.P. was 
funded by an MRC CRTF (MR/K002813/1). C.A., L.P-C., 
and C.M.D-C. have held grants from the Spanish Ministry 
of Economy, Industry and Competitiveness. Instituto 
de Salud Carlos III, co-financed by ERDF Funds from 
the European Commission, “A way of making Europe,” 
CIBERSAM, Madrid Regional Government (S2010/
BMD-2422 AGES), European Union Structural Funds and 
European Union Seventh Framework Program under grant 
agreements FP7-HEALTH-2009-2.2.1-2-241909 (EU-GEI), 
FP7-HEALTH-2009-2.2.1-3-242114 (OPTiMISE), FP7-
HEALTH-2013-2.2.1-2-603196 (PSYSCAN)and FP7- 
HEALTH-2013-2.2.1-2-602478 (METSY); European 
Union H2020 Program under the Innovative Medicines 
Initiative 2 Joint Undertaking (grant agreement No-115916; 
PRISM); Fundación Alicia Koplowitz and Fundación 
Mutua Madrileña. M.H., J.H.M. and H.S. receive salary sup-
port from the National Institute for Health Research (NIHR) 
Biomedical Research Centre at South London and Maudsley 
NHS Foundation Trust and King’s College London. The 
views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR or the Department of Health.
Acknowledgment
The authors declare that there are no conflicts of interest 
in relation to the subject of this study.
References
 1. Díaz-Caneja CM, Pina-Camacho L, Rodríguez-Quiroga A, 
Fraguas D, Parellada M, Arango C. Predictors of outcome 
in early-onset psychosis: a systematic review. NPJ Schizophr. 
2015;1:14005.
 2. World Health Organisation. The ICD-10 Classification of 
Mental and Behavioural Disorders: Clinical Descriptions and 
Diagnostic Guidelines. Geneva, Switzerland: World Health 
Organisation; 1992.
 3. Schimmelmann BG, Conus P, Cotton S, McGorry PD, 
Lambert M. Pre-treatment, baseline, and outcome differences 
between early-onset and adult-onset psychosis in an epide-
miological cohort of 636 first-episode patients. Schizophr Res. 
2007;95:1–8.
 4. Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll 
CU, Jeppesen P. Clinical characteristics and predictors 
of outcome of schizophrenia-spectrum psychosis in chil-
dren and adolescents: a systematic review. J Child Adolesc 
Psychopharmacol. 2016;26:410–427.
 5. Strauss JS, Carpenter WT, Jr., Bartko JJ. The diagnosis and 
understanding of schizophrenia. Part III. speculations on the 
processes that underlie schizophrenic symptoms and signs. 
Schizophr Bull. 1974;11:61–69.
 6. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 
“just the facts” 4.  clinical features and conceptualization. 
Schizophr Res. 2009;110:1–23.
 7. Bobes J, Arango C, Garcia-Garcia M, Rejas J; CLAMORS 
Study Collaborative Group. Prevalence of negative symptoms 
in outpatients with schizophrenia spectrum disorders treated 
with antipsychotics in routine clinical practice: findings from 
the CLAMORS study. J Clin Psychiatry. 2010;71:280–286.
 8. Patel R, Jayatilleke N, Broadbent M, et al. Negative symp-
toms in schizophrenia: a study in a large clinical sample 
of patients using a novel automated method. BMJ Open. 
2015;5:e007619.
 9. Álvarez-Jiménez M, Gleeson JF, Henry LP, et  al. Road to 
full recovery: longitudinal relationship between symptomatic 
remission and psychosocial recovery in first-episode psycho-
sis over 7.5 years. Psychol Med. 2012;42:595–606.
 10. Austin SF, Mors O, Secher RG, et al. Predictors of recovery 
in first episode psychosis: the OPUS cohort at 10 year follow-
up. Schizophr Res. 2013;150:163–168.
 11. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values 
of neurocognition and negative symptoms on functional out-
come in schizophrenia: a longitudinal first-episode study with 
7-year follow-up. Am J Psychiatry. 2005;162:495–506.
 12. White C, Stirling J, Hopkins R, et  al. Predictors of 
10-year outcome of first-episode psychosis. Psychol Med. 
2009;39:1447–1456.
 13. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A 
separate disease within the syndrome of schizophrenia. Arch 
Gen Psychiatry. 2001;58:165–171.
 14. Parellada M, Castro-Fornieles J, Gonzalez-Pinto A, et  al. 
Predictors of functional and clinical outcome in early-
onset first-episode psychosis: the child and adolescent first 
episode of psychosis (CAFEPS) study. J Clin Psychiatry. 
2015;76:e1441–e1448.
 15. Strauss GP, Allen DN, Miski P, Buchanan RW, Kirkpatrick 
B, Carpenter WT Jr. Differential patterns of premorbid 
social and academic deterioration in deficit and nondeficit 
schizophrenia. Schizophr Res. 2012;135:134–138.
 16. Rapado-Castro M, Soutullo C, Fraguas D, et al. Predominance 
of symptoms over time in early-onset psychosis: a principal 
component factor analysis of the positive and negative syn-
drome scale. J Clin Psychiatry. 2010;71:327–337.
 17. Chang WC, Tang JY, Hui CL, et  al. The relationship of 
early premorbid adjustment with negative symptoms 
and cognitive functions in first-episode schizophrenia: a 
prospective three-year follow-up study. Psychiatry Res. 
2013;209:353–360.
 18. Hassan GA, Taha GR. Long term functioning in early onset 
psychosis: two years prospective follow-up study. Behav Brain 
Funct. 2011;7:28.
 19. Vyas NS, Hadjulis M, Vourdas A, Byrne P, Frangou S. The 
Maudsley early onset schizophrenia study. Predictors of psy-
chosocial outcome at 4-year follow-up. Eur Child Adolesc 
Psychiatry. 2007;16:465–470.
 20. Stewart R, Davis K. ‘Big data’ in mental health research: 
current status and emerging possibilities. Soc Psychiatry 
Psychiatr Epidemiol. 2016;51:1055–1072.
Downloaded from https://academic.oup.com/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sbx197/4823016
by King's College London user
on 25 January 2018
Page 11 of 11
Negative Symptoms and Treatment Failure in EOP
 21. Daniel DG. Issues in selection of instruments to measure 
negative symptoms. Schizophr Res. 2013;150:343–345.
 22. Fields JH, Grochowski S, Lindenmayer JP, et al. Assessing 
positive and negative symptoms in children and adolescents. 
Am J Psychiatry. 1994;151:249–253.
 23. Kay SR, Fiszbein A, Opler LA. The positive and negative 
syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 
1987;13:261–276.
 24. Kapila A, Fisher HL, Johnson S, et al. Clinical and demographic 
differences between patients with manic, depressive and schiz-
ophrenia-spectrum psychoses presenting to early intervention 
services in London [published online ahead of print October 
15, 2017]. Early Interv Psychiatry. doi:10.1111/eip.12511.
 25. Tasma M, Swart M, Wolters G, et  al. Do routine outcome 
monitoring results translate to clinical practice? A  cross-
sectional study in patients with a psychotic disorder. BMC 
Psychiatry. 2016;16:107.
 26. Chowdhury GG. Natural language processing. Annu Rev Inf 
Sci Technol. 2003;37:51–89.
 27. Liao KP, Cai T, Savova GK, et al. Development of phenotype 
algorithms using electronic medical records and incorporat-
ing natural language processing. BMJ. 2015;350:h1885.
 28. Murphy SN, Weber G, Mendis M, et al. Serving the enter-
prise and beyond with informatics for integrating biology and 
the bedside (i2b2). J Am Med Inform Assoc. 2010;17:124–130.
 29. Downs JM, Lechler S, Dean H, et al. The association between 
comorbid autism spectrum disorders and antipsychotic treat-
ment failure in early-onset psychosis: a historical cohort study 
using electronic health records [published online ahead of print 
November 7, 2017]. J Clin Psychiatry. doi:10.4088/JCP.16m11422
 30. Demjaha A, Egerton A, Murray RM, et  al. Antipsychotic 
treatment resistance in schizophrenia associated with ele-
vated glutamate levels but normal dopamine function. Biol 
Psychiatry. 2014;75:e11–e13.
 31. Laruelle M. Schizophrenia: from dopaminergic to glutamater-
gic interventions. Curr Opin Pharmacol. 2014;14:97–102.
 32. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of 
treatment response from a first episode of schizophrenia or 
schizoaffective disorder. Am J Psychiatry. 1999;156:544–549.
 33. Boeing L, Murray V, Pelosi A, McCabe R, Blackwood D, 
Wrate R. Adolescent-onset psychosis: prevalence, needs and 
service provision. Br J Psychiatry. 2007;190:18–26.
 34. Downs J, Gilbert R, Hayes RD, Hotopf M, Ford T. Linking 
health and education data to plan and evaluate services for 
children. Arch Dis Child. 2017;102:599–602.
 35. Perera G, Broadbent M, Callard F, et al. Cohort profile of 
the South London and maudsley NHS foundation trust bio-
medical research centre (SLaM BRC) case register: current 
status and recent enhancement of an electronic mental health 
record-derived data resource. BMJ Open. 2016;6:e008721.
 36. Cunningham H, Tablan V, Roberts A, Bontcheva K. Getting 
more out of biomedical documents with GATE’s full lifecycle 
open source text analytics. PLoS Comput Biol. 2013;9:e1002854.
 37. Jackson MSc RG, Ball M, Patel R, Hayes RD, Dobson RJ, 
Stewart R. TextHunter–A user friendly tool for extracting 
generic concepts from free text in clinical research. AMIA 
Annu Symp Proc. 2014;2014:729–738.
 38. Downs J, Hotopf M, Ford T, et al. Clinical predictors of antip-
sychotic use in children and adolescents with autism spectrum 
disorders: a historical open cohort study using electronic health 
records. Eur Child Adolesc Psychiatry. 2016;25:649–658.
 39. Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on 
premature mortality: an assessment of clinical monitoring and 
other potential confounders. Schizophr Bull. 2015;41:644–655.
 40. Schneider C, Papachristou E, Wimberley T, et al. Clozapine 
use in childhood and adolescent schizophrenia: a nation-
wide population-based study. Eur Neuropsychopharmacol. 
2015;25:857–863.
 41. Suzuki T, Remington G, Mulsant BH, et al. Defining treat-
ment-resistant schizophrenia and response to antipsychotics: 
a review and recommendation. Psychiatry Res. 2012;197:1–6.
 42. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study 
group. Effectiveness of antipsychotic drugs in first-episode 
schizophrenia and schizophreniform disorder: an open ran-
domised clinical trial. Lancet. 2008;371:1085–1097.
 43. Lieberman JA, Stroup TS, McEvoy JP, et  al.; Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
Investigators. Effectiveness of antipsychotic drugs in patients 
with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
 44. Patel R, Wilson R, Jackson R, et al. Association of cannabis 
use with hospital admission and antipsychotic treatment fail-
ure in first episode psychosis: an observational study. BMJ 
Open. 2016;6:e009888.
 45. Marder SR, Davis JM, Chouinard G. The effects of risperi-
done on the five dimensions of schizophrenia derived by fac-
tor analysis: combined results of the North American trials. J 
Clin Psychiatry. 1997;58:538–546.
 46. McLennan D, Barnes H, Noble M, Davies J, Garratt E, Dibben 
C. The English Indices of Deprivation 2010. London, UK: 
Department of Communities and Local Government 2011.
 47. Jackson RG, Patel R, Jayatilleke N, et al. Natural language 
processing to extract symptoms of severe mental illness 
from clinical text: the Clinical Record Interactive Search 
Comprehensive Data Extraction (CRIS-CODE) project BMJ 
Open 2017;7:e012012. doi: 10.1136/bmjopen-2016-012012 
 48. Shaffer D, Gould MS, Brasic J, et al. A children’s global assess-
ment scale (CGAS). Arch Gen Psychiatry. 1983;40:1228–1231.
 49. Sarkar S, Hillner K, Velligan DI. Conceptualization and 
treatment of negative symptoms in schizophrenia. World J 
Psychiatry. 2015;5:352–361.
 50. Perivoliotis D, Morrison AP, Grant PM, French P, Beck AT. 
Negative performance beliefs and negative symptoms in indi-
viduals at ultra-high risk of psychosis: a preliminary study. 
Psychopathology. 2009;42:375–379.
 51. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms 
of schizophrenia: clinical characteristics, pathophysiological 
substrates, experimental models and prospects for improved 
treatment. Eur Neuropsychopharmacol. 2014;24:645–692.
 52. Howes OD, Kapur S. A neurobiological hypothesis for the clas-
sification of schizophrenia: type A (hyperdopaminergic) and 
type B (normodopaminergic). Br J Psychiatry. 2014;205:1–3.
 53. Hunter R, Barry S. Negative symptoms and psychosocial 
functioning in schizophrenia: neglected but important targets 
for treatment. Eur Psychiatry. 2012;27:432–436.
 54. Gilbody SM, House AO, Sheldon TA. Psychiatrists in the 
UK do not use outcomes measures. National survey. Br J 
Psychiatry. 2002;180:101–103.
 55. Zimmerman M, McGlinchey JB. Why don’t psychiatrists use 
scales to measure outcome when treating depressed patients? 
J Clin Psychiatry. 2008;69:1916–1919.
 56. Roberts A. Language, structure, and reuse in the electronic 
health record. AMA J Ethics. 2017;19:281–288.
 57. Campbell F, Biggs K, Aldiss SK, et al. Transition of care for 
adolescents from paediatric services to adult health services. 
Cochrane Database Syst Rev. 2016;4:CD009794
 58. Green J. Annotation: the therapeutic alliance–a significant 
but neglected variable in child mental health treatment stud-
ies. J Child Psychol Psychiatry. 2006;47:425–435.
Downloaded from https://academic.oup.com/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sbx197/4823016
by King's College London user
on 25 January 2018
